Keeping Track: Oxbryta Approval Headlines Pre-Thanksgiving Week Of News
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Keeping Track: Vascepa Adds CV Risk Reduction Claim, Vyondys 53 Get A Stunning Approval, And Submissions Pour Into FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
US FDA Puts Spotlight On Alkermes' Violative Vivitrol Ad
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.
Keeping Track Of User Fee Decisions And Filings: Adakveo, Brukinsa And Fetroja Mark Massive Week Of Novel Approvals
The latest news on US FDA user fee decisions and submissions to the agency.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: